Concord Biotech Q2 Results
- BSE: 543960
- NSE: CONCORDBIO
- ISIN: INE338H01029
- Sector: Biotechnology & Drugs
BSE
1,225.60
-18.85 (-1.51%)
-18.85 (-1.51%)Volume5.91 K
Updated: Thu 12 Feb, 2026 | 12:34:12
NSE
1,224-20.80 (-1.67%)
-20.80 (-1.67%)Volume1.60 L
Updated: Thu 12 Feb, 2026 | 12:33:46
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹247.06 Cr.(-20.35%)
- Operating Profit₹70.10 Cr.(-43.18%)
- Profit After Tax₹63.06 Cr.(-34.13%)
- Operating Margin28.37%(-28.66%)
Note: Comparison is on YoY basis
Quarterly - Concord Biotech Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 176.96 | 160.37 | 10.35% | 186.82 | -5.28% |
| Depreciation/ Amortization | 18.39 | 17.78 | 3.46% | 13.31 | 38.13% |
| Operating Income | 70.10 | 43.62 | 60.70% | 123.36 | -43.18% |
| Net Income | 63.06 | 44.06 | 43.14% | 95.74 | -34.13% |
| Other Operating Expenses Total | 36.57 | 30.11 | 21.43% | 63.52 | -42.43% |
| Net Income Before Taxes | 85.68 | 58.73 | 45.89% | 130.34 | -34.26% |
| Total Revenue | 247.06 | 203.99 | 21.11% | 310.18 | -20.35% |
| Selling/ General/ Admin Expenses Total | 44.46 | 37.90 | 17.30% | 33.66 | 32.06% |
| Diluted Normalized EPS | 6.01 | 4.21 | 42.76% | 14.85 | -59.53% |